SYNTARA LIMITED - Announcements

Market Cap $27.46M Add to my watchlist

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug... Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.More

Announcements

Filter Results

All Price Sensitive Only

SNT	CEO Presentation to 2019 AusBiotech Conference		30/10/19	2.02MB	Share
SNT	FDA Provides Guidance on Bronchitol Approval Steps	PRICE SENSITIVE	28/10/19	103.32KB	Share
SNT	Pharmaxis Cancer Drug Progressing in Clinic		24/10/19	155.87KB	Share
SNT	Appendix 4G		18/10/19	91.67KB	Share
SNT	Corporate Governance Statement		18/10/19	83.79KB	Share
SNT	Notice of Annual General Meeting/Proxy Form		18/10/19	324.28KB	Share
SNT	Annual Report to shareholders		18/10/19	781.33KB	Share
SNT	Pharmaxis Receives $6.2m R&D Tax Incentive	PRICE SENSITIVE	17/10/19	101.81KB	Share
SNT	Appendix 3B - Exercise of Employee Options		12/09/19	127.92KB	Share
SNT	Proposed Issue of Securities to CEO		15/08/19	110.85KB	Share
SNT	Appendix 3B 2019 Grant of Performance Rights and Share Plan		15/08/19	130.57KB	Share
SNT	Change of Director's Interest Notice-G Phillips Rights Lapse		15/08/19	70.43KB	Share
SNT	Lapse of 2018 Performance Rights and Expiry of Options		15/08/19	107.35KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	15/08/19	870.85KB	Share
SNT	Investor Presentation		26/07/19	1.66MB	Share
SNT	Quarterly Shareholder Update - June 2019	PRICE SENSITIVE	25/07/19	395.58KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	25/07/19	120.79KB	Share
SNT	Pathway to US Bronchitol Approval Clarified in FDA Response	PRICE SENSITIVE	20/06/19	103.01KB	Share
SNT	Change in substantial holding		30/05/19	372.92KB	Share
SNT	US Advisory Committee Positive Recommendation on Bronchitol	PRICE SENSITIVE	09/05/19	134.45KB	Share
SNT	Quarterly Shareholder Update - March 2019	PRICE SENSITIVE	29/04/19	390.02KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/19	123.23KB	Share
SNT	Appendix 3B - Exercise of Employee Options		18/04/19	128.12KB	Share
SNT	Investor Presentation		01/04/19	1.64MB	Share
SNT	US FDA Convenes Advisory Committee for Bronchitol		26/03/19	100.72KB	Share
SNT	Becoming a substantial holder		05/03/19	255.44KB	Share
SNT	Ceasing to be a substantial holder		04/03/19	9.43KB	Share
SNT	Boehringer Completes Enrollment of Phase 2A Trial in NASH		25/02/19	103.99KB	Share
SNT	Pharmaxis Commences Phase 1 LOX Clinical Trial	PRICE SENSITIVE	22/02/19	128.88KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	14/02/19	553.93KB	Share
SNT	Quarterly Shareholder Update - December 2018	PRICE SENSITIVE	30/01/19	385.27KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/19	120.71KB	Share
SNT	Pharmaxis Announces LOXL2 Program Phase 2 Ready	PRICE SENSITIVE	17/01/19	116.23KB	Share
SNT	PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USA	PRICE SENSITIVE	20/12/18	114.21KB	Share
SNT	Pharmaxis Announces First Relaunch Sales of Aridol in USA	PRICE SENSITIVE	13/12/18	116.72KB	Share
SNT	Change in substantial holding		27/11/18	246.08KB	Share
SNT	Appendix 3B - exercise of employee options		26/11/18	128.19KB	Share
SNT	Final Director's Interest Notice		22/11/18	63.16KB	Share
SNT	Change of Director's Interest Notice		22/11/18	70.48KB	Share
SNT	Appendix 3B - Grant of options to CEO		22/11/18	130.2KB	Share
SNT	Results of Meeting		22/11/18	83.09KB	Share
SNT	Pharmaxis AGM - CEO Presentation	PRICE SENSITIVE	22/11/18	1.17MB	Share
SNT	Chairman's Address to Shareholders	PRICE SENSITIVE	22/11/18	108.27KB	Share
SNT	Pharmaxis AGM - Withdrawal of Resolution		22/11/18	75.95KB	Share
SNT	Investor Research Briefing Presentations		20/11/18	3.31MB	Share
SNT	LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready	PRICE SENSITIVE	20/11/18	146.6KB	Share
SNT	Pharmaxis Releases Positive Results of Phase 1 Clinical Tria	PRICE SENSITIVE	15/11/18	117.37KB	Share
SNT	Pharmaxis Investor Research Briefing		15/11/18	113.15KB	Share
SNT	Quarterly Shareholder Update - September 2018		26/10/18	376.27KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	26/10/18	122.69KB	Share
SNT	Copy of Corporate Governance Statement		19/10/18	61.78KB	Share
SNT	Appendix 4G		19/10/18	120.63KB	Share
SNT	Annual Report to shareholders		19/10/18	871.33KB	Share
SNT	Notice of Annual General Meeting/Proxy Form		19/10/18	451.03KB	Share
SNT	Updated Investor Presentation		11/10/18	1.21MB	Share
SNT	Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor	PRICE SENSITIVE	11/10/18	117.56KB	Share
SNT	Director Retirement		04/10/18	113.05KB	Share
SNT	Change in substantial holding		26/09/18	75.67KB	Share
SNT	Appendix 3B - exercise of employee options		26/09/18	128.22KB	Share
SNT	Change in substantial holding		25/09/18	218.37KB	Share
SNT	Change in substantial holding from AEF		25/09/18	144.8KB	Share
SNT	Appendix 3B - exercise of 25,000 employee options		21/09/18	128.22KB	Share
SNT	Change of Director's Interest Notice - Metters		21/09/18	69.92KB	Share
SNT	Change of Director's Interest Notice - W Delaat		21/09/18	70.36KB	Share
SNT	Change of Director's Interest Notice - Phillips		21/09/18	71.89KB	Share
SNT	Change of Director's Interest Notice - McComas		21/09/18	70.99KB	Share
SNT	Change of Director's Interest Notice - S Buckingham		21/09/18	71.13KB	Share
SNT	Section 708A Notice		21/09/18	52.63KB	Share
SNT	Appendix 3B - Placement Tranche 2		21/09/18	129.12KB	Share
SNT	Initial Director's Interest Notice - E Rayner		18/09/18	66.28KB	Share
SNT	Director Appointment - Edward Rayner		18/09/18	114.57KB	Share
SNT	Results of Meeting		17/09/18	230.81KB	Share
SNT	Chairman's Introductory Comments to Shareholders		17/09/18	88.48KB	Share
SNT	Investor Presentation		28/08/18	1.3MB	Share
SNT	Notice of Extraordinary General Meeting/Proxy Form		20/08/18	614.56KB	Share
SNT	Notice of initial substantial holder		17/08/18	296.1KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	17/08/18	921.26KB	Share
SNT	Change in substantial holding		16/08/18	63.62KB	Share
SNT	FDA Factory Approval and Relaunch of Aridol in US Market	PRICE SENSITIVE	15/08/18	124.73KB	Share
SNT	Section 708A Notice		14/08/18	52.63KB	Share
SNT	Appendix 3B - Placement Tranche 1		14/08/18	137.83KB	Share
SNT	Capital Raising Presentation	PRICE SENSITIVE	06/08/18	1.27MB	Share
SNT	Pharmaxis Announces A$24m Placement	PRICE SENSITIVE	06/08/18	127.66KB	Share
SNT	Trading Halt Announcement - System Upgrade	PRICE SENSITIVE	06/08/18	220.36KB	Share
SNT	Trading Halt	PRICE SENSITIVE	03/08/18	271.05KB	Share
SNT	Quarterly Shareholder Update - June 2018	PRICE SENSITIVE	27/07/18	441.24KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/18	122.6KB	Share
SNT	Proposed Issue of Securities to Chief Executive Officer		25/07/18	111.76KB	Share
SNT	Appendix 3B - Grant of Employee Options and Shares		25/07/18	130.93KB	Share
SNT	Appendix 3B - Exercise of Employee Options		25/07/18	129.31KB	Share
SNT	Appendix 3B - Exercise of Employee Options		17/07/18	129.32KB	Share
SNT	Change of Director's Interest Notice - Expiring Options		02/07/18	71.02KB	Share
SNT	LOXL2 Program Attracts Strong Partner Interest at BIO18	PRICE SENSITIVE	14/06/18	120.63KB	Share
SNT	Quarterly Shareholder Update - March 2018	PRICE SENSITIVE	30/04/18	375.62KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18	194.74KB	Share
SNT	Change in substantial holding		05/04/18	215.26KB	Share
SNT	Change in substantial holding from AEF		04/04/18	152.95KB	Share
SNT	Appendix 3B - Exercise of Employee Options		08/03/18	130.63KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	15/02/18	241.7KB	Share
SNT	Investor Presentation - 7 February 2018		07/02/18	1.24MB	Share

SNT CEO Presentation to 2019 AusBiotech Conference
30/10/19		2.02MB	Share
SNT FDA Provides Guidance on Bronchitol Approval Steps
28/10/19	PRICE SENSITIVE	103.32KB	Share
SNT Pharmaxis Cancer Drug Progressing in Clinic
24/10/19		155.87KB	Share
SNT Appendix 4G
18/10/19		91.67KB	Share
SNT Corporate Governance Statement
18/10/19		83.79KB	Share
SNT Notice of Annual General Meeting/Proxy Form
18/10/19		324.28KB	Share
SNT Annual Report to shareholders
18/10/19		781.33KB	Share
SNT Pharmaxis Receives $6.2m R&D Tax Incentive
17/10/19	PRICE SENSITIVE	101.81KB	Share
SNT Appendix 3B - Exercise of Employee Options
12/09/19		127.92KB	Share
SNT Proposed Issue of Securities to CEO
15/08/19		110.85KB	Share
SNT Appendix 3B 2019 Grant of Performance Rights and Share Plan
15/08/19		130.57KB	Share
SNT Change of Director's Interest Notice-G Phillips Rights Lapse
15/08/19		70.43KB	Share
SNT Lapse of 2018 Performance Rights and Expiry of Options
15/08/19		107.35KB	Share
SNT Preliminary Final Report
15/08/19	PRICE SENSITIVE	870.85KB	Share
SNT Investor Presentation
26/07/19		1.66MB	Share
SNT Quarterly Shareholder Update - June 2019
25/07/19	PRICE SENSITIVE	395.58KB	Share
SNT Appendix 4C - quarterly
25/07/19	PRICE SENSITIVE	120.79KB	Share
SNT Pathway to US Bronchitol Approval Clarified in FDA Response
20/06/19	PRICE SENSITIVE	103.01KB	Share
SNT Change in substantial holding
30/05/19		372.92KB	Share
SNT US Advisory Committee Positive Recommendation on Bronchitol
09/05/19	PRICE SENSITIVE	134.45KB	Share
SNT Quarterly Shareholder Update - March 2019
29/04/19	PRICE SENSITIVE	390.02KB	Share
SNT Appendix 4C - quarterly
29/04/19	PRICE SENSITIVE	123.23KB	Share
SNT Appendix 3B - Exercise of Employee Options
18/04/19		128.12KB	Share
SNT Investor Presentation
01/04/19		1.64MB	Share
SNT US FDA Convenes Advisory Committee for Bronchitol
26/03/19		100.72KB	Share
SNT Becoming a substantial holder
05/03/19		255.44KB	Share
SNT Ceasing to be a substantial holder
04/03/19		9.43KB	Share
SNT Boehringer Completes Enrollment of Phase 2A Trial in NASH
25/02/19		103.99KB	Share
SNT Pharmaxis Commences Phase 1 LOX Clinical Trial
22/02/19	PRICE SENSITIVE	128.88KB	Share
SNT Half Yearly Report and Accounts
14/02/19	PRICE SENSITIVE	553.93KB	Share
SNT Quarterly Shareholder Update - December 2018
30/01/19	PRICE SENSITIVE	385.27KB	Share
SNT Appendix 4C - quarterly
30/01/19	PRICE SENSITIVE	120.71KB	Share
SNT Pharmaxis Announces LOXL2 Program Phase 2 Ready
17/01/19	PRICE SENSITIVE	116.23KB	Share
SNT PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USA
20/12/18	PRICE SENSITIVE	114.21KB	Share
SNT Pharmaxis Announces First Relaunch Sales of Aridol in USA
13/12/18	PRICE SENSITIVE	116.72KB	Share
SNT Change in substantial holding
27/11/18		246.08KB	Share
SNT Appendix 3B - exercise of employee options
26/11/18		128.19KB	Share
SNT Final Director's Interest Notice
22/11/18		63.16KB	Share
SNT Change of Director's Interest Notice
22/11/18		70.48KB	Share
SNT Appendix 3B - Grant of options to CEO
22/11/18		130.2KB	Share
SNT Results of Meeting
22/11/18		83.09KB	Share
SNT Pharmaxis AGM - CEO Presentation
22/11/18	PRICE SENSITIVE	1.17MB	Share
SNT Chairman's Address to Shareholders
22/11/18	PRICE SENSITIVE	108.27KB	Share
SNT Pharmaxis AGM - Withdrawal of Resolution
22/11/18		75.95KB	Share
SNT Investor Research Briefing Presentations
20/11/18		3.31MB	Share
SNT LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready
20/11/18	PRICE SENSITIVE	146.6KB	Share
SNT Pharmaxis Releases Positive Results of Phase 1 Clinical Tria
15/11/18	PRICE SENSITIVE	117.37KB	Share
SNT Pharmaxis Investor Research Briefing
15/11/18		113.15KB	Share
SNT Quarterly Shareholder Update - September 2018
26/10/18		376.27KB	Share
SNT Appendix 4C - quarterly
26/10/18	PRICE SENSITIVE	122.69KB	Share
SNT Copy of Corporate Governance Statement
19/10/18		61.78KB	Share
SNT Appendix 4G
19/10/18		120.63KB	Share
SNT Annual Report to shareholders
19/10/18		871.33KB	Share
SNT Notice of Annual General Meeting/Proxy Form
19/10/18		451.03KB	Share
SNT Updated Investor Presentation
11/10/18		1.21MB	Share
SNT Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor
11/10/18	PRICE SENSITIVE	117.56KB	Share
SNT Director Retirement
04/10/18		113.05KB	Share
SNT Change in substantial holding
26/09/18		75.67KB	Share
SNT Appendix 3B - exercise of employee options
26/09/18		128.22KB	Share
SNT Change in substantial holding
25/09/18		218.37KB	Share
SNT Change in substantial holding from AEF
25/09/18		144.8KB	Share
SNT Appendix 3B - exercise of 25,000 employee options
21/09/18		128.22KB	Share
SNT Change of Director's Interest Notice - Metters
21/09/18		69.92KB	Share
SNT Change of Director's Interest Notice - W Delaat
21/09/18		70.36KB	Share
SNT Change of Director's Interest Notice - Phillips
21/09/18		71.89KB	Share
SNT Change of Director's Interest Notice - McComas
21/09/18		70.99KB	Share
SNT Change of Director's Interest Notice - S Buckingham
21/09/18		71.13KB	Share
SNT Section 708A Notice
21/09/18		52.63KB	Share
SNT Appendix 3B - Placement Tranche 2
21/09/18		129.12KB	Share
SNT Initial Director's Interest Notice - E Rayner
18/09/18		66.28KB	Share
SNT Director Appointment - Edward Rayner
18/09/18		114.57KB	Share
SNT Results of Meeting
17/09/18		230.81KB	Share
SNT Chairman's Introductory Comments to Shareholders
17/09/18		88.48KB	Share
SNT Investor Presentation
28/08/18		1.3MB	Share
SNT Notice of Extraordinary General Meeting/Proxy Form
20/08/18		614.56KB	Share
SNT Notice of initial substantial holder
17/08/18		296.1KB	Share
SNT Preliminary Final Report
17/08/18	PRICE SENSITIVE	921.26KB	Share
SNT Change in substantial holding
16/08/18		63.62KB	Share
SNT FDA Factory Approval and Relaunch of Aridol in US Market
15/08/18	PRICE SENSITIVE	124.73KB	Share
SNT Section 708A Notice
14/08/18		52.63KB	Share
SNT Appendix 3B - Placement Tranche 1
14/08/18		137.83KB	Share
SNT Capital Raising Presentation
06/08/18	PRICE SENSITIVE	1.27MB	Share
SNT Pharmaxis Announces A$24m Placement
06/08/18	PRICE SENSITIVE	127.66KB	Share
SNT Trading Halt Announcement - System Upgrade
06/08/18	PRICE SENSITIVE	220.36KB	Share
SNT Trading Halt
03/08/18	PRICE SENSITIVE	271.05KB	Share
SNT Quarterly Shareholder Update - June 2018
27/07/18	PRICE SENSITIVE	441.24KB	Share
SNT Appendix 4C - quarterly
27/07/18	PRICE SENSITIVE	122.6KB	Share
SNT Proposed Issue of Securities to Chief Executive Officer
25/07/18		111.76KB	Share
SNT Appendix 3B - Grant of Employee Options and Shares
25/07/18		130.93KB	Share
SNT Appendix 3B - Exercise of Employee Options
25/07/18		129.31KB	Share
SNT Appendix 3B - Exercise of Employee Options
17/07/18		129.32KB	Share
SNT Change of Director's Interest Notice - Expiring Options
02/07/18		71.02KB	Share
SNT LOXL2 Program Attracts Strong Partner Interest at BIO18
14/06/18	PRICE SENSITIVE	120.63KB	Share
SNT Quarterly Shareholder Update - March 2018
30/04/18	PRICE SENSITIVE	375.62KB	Share
SNT Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE	194.74KB	Share
SNT Change in substantial holding
05/04/18		215.26KB	Share
SNT Change in substantial holding from AEF
04/04/18		152.95KB	Share
SNT Appendix 3B - Exercise of Employee Options
08/03/18		130.63KB	Share
SNT Half Yearly Report and Accounts
15/02/18	PRICE SENSITIVE	241.7KB	Share
SNT Investor Presentation - 7 February 2018
07/02/18		1.24MB	Share

REFRESH

First 3 4 5 6 7

(20min delay)
Last 2.4¢		Change -0.002(7.69%)		Mkt cap ! $27.46M

Open	High	Low	Value	Volume
2.5¢	2.6¢	2.3¢	$24.40K	1.024M

Buyers (Bids)

No.	Vol.	Price($)
4	227076	2.3¢

Sellers (Offers)

Price($)	Vol.	No.
2.4¢	181768	2

View Market Depth

No.	Vol.	Price($)
4	227076	0.023
3	93000	0.022
5	793867	0.021
13	3917674	0.020
3	1026988	0.019

Price($)	Vol.	No.
0.024	181768	2
0.025	159960	3
0.027	250000	2
0.029	347870	2
0.030	358058	3

Last trade - 14.22pm 21/06/2024 (20 minute delay)


Last 2.3¢		Change -0.002 ( 11.5 %)
Open	High	Low	Volume
2.5¢	2.5¢	2.3¢	548912
Last updated 15.00pm 21/06/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories